Companies press releases
19 Oct, 2023, 07:30 ET 7 Consecutive Quarters of Double-Digit Growth in Product Revenue and Prescriptions Dispensed $4.6 million in Gross Product Revenue 11% growth over prior quarter; 100% growth over comparable quarter last year $2.1 million in Net Product Revenue 18% growth over prior quarter; 137% growth over comparable quarter last year Prescriptions Dispensed […]
18 Oct, 2023, 07:30 ET Positive data with Palatin’s melanocortin-4 receptor (MC4R) agonist plus glucagon like peptide-1 (GLP-1) presented at the Peptide Therapeutics Symposium GLP-1 & MC4R agonist co-administration data shows increased weight loss and greater glucose control above monotherapy Preclinical data and prior clinical studies support the further clinical development and commercial potential of
16 Oct, 2023, 07:30 ET Data demonstrates oral PL8177 causes diseased colons to move to a healthier state Provides further support for ongoing oral PL8177 Phase 2 ulcerative colitis study CRANBURY, N.J., Oct. 16, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system,
13 Oct, 2023, 16:15 ET Palatin to Deliver Plan of Compliance to NYSE American CRANBURY, N.J., Oct. 13, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced it received a notice from the staff of
Palatin Receives Notice of Non-Compliance from NYSE American Read More »
28 Sep, 2023, 07:30 ET Enrollment in Phase 3 PL9643 MELODY-1 Study in Dry Eye Disease (DED) is Complete with 570 Patients Enrolled Topline Data Expected Late 4Q Calendar Year 2023 Interim Analysis of Initial 120 Patients Showed Statistical Separation for Clinical Efficacy Across Multiple Signs and Symptoms of Dry Eye Excellent Patient Safety and Tolerability Product
22 Sep, 2023, 16:00 ET CRANBURY, N.J., Sept. 22, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2023, before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted
07 Sep, 2023, 16:00 ET CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the melanocortin receptor system, today announced that management will present at H.C. Wainwright 25th Annual Global Investment Conference taking place September 11-13, 2023
Palatin to Present at the H.C. Wainwright 25th Annual Global Investment Conference Read More »
07 Sep, 2023, 07:30 ET Topline data currently expected late 4Q calendar 2023 Interim analysis of first 120 patients demonstrated: Excellent safety and tolerability product profile Potential for PL9643 to address multiple signs and symptoms of dry eye disease CRANBURY, N.J., Sept. 7, 2023 /PRNewswire/ — Palatin Technologies, Inc. (NYSE American: PTN), a biopharmaceutical company developing
10 Aug, 2023, 07:30 ET ~30-40% of ED patients do not respond to PDE5i treatment Published clinical data and mechanisms of action support clinical study of bremelanotide in combination with a PDE5i Successfully co-formulated bremelanotide with a PDE5i Phase 2 clinical study in PDE5i non-responder ED patients currently expected to commence in 4Q 2023 CRANBURY, N.J., Aug.
08 Aug, 2023, 07:30 ET First prescription dispensed in Chinese Hainan Province 93% of patients enrolled completed the Phase 3 trial in premenopausal patients with Hypoactive Sexual Desire Disorder (HSDD) in South Korea Data expected later this year Supports submission to Korean Ministry of Food & Drug Safety (MFDS) for Marketing Approval CRANBURY, N.J., Aug.
